
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. has demonstrated a strong financial performance, evident from a gross margin increase to 71.6%, which is above consensus expectations and reflects a year-over-year improvement of 980 basis points. The company experienced a significant revenue boost, with Light Adjustable Lens (LAL) revenue reaching $28.5 million, a 60% increase, while Light Delivery Device (LDD) revenue remained stable at $10.7 million, up 7%. Analysts project that RxSight can maintain double-digit growth due to rising utilization rates among an expanding LDD installed base, alongside anticipated improvements in margins driven by higher volumes of LAL sales.
Bears say
RxSight Inc. has demonstrated a concerning deceleration in LAL utilization growth, which dropped to 9% year-over-year in 4Q24, down from the previous range of 17%-22% observed in preceding quarters. The company has also reported stagnant or declining U.S. IOL sales amidst challenging market conditions, exacerbating concerns regarding its market share and revenue growth potential. Additionally, decreased earnings per share estimates for 2025 and 2026, along with risks including clinical challenges, competition, and potential dilutive financing, further reinforce a negative outlook for the company’s financial stability.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares